NCT06414954 2026-04-13
SYNAPSE-MG
NMD Pharma A/S
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06987539 2026-04-07
THYME
Amgen
Phase 2 Recruiting
NCT07501702 2026-03-30
ETNA
Vertex Pharmaceuticals Incorporated
Phase 2 Not yet recruiting
NCT00716066 2026-02-27
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT07284420 2026-02-09
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Phase 2 Recruiting
NCT06282159 2025-10-07
MAGIC
Dianthus Therapeutics
Phase 2 Active not recruiting
NCT04226170 2025-09-11
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
DAS-MG, Inc
Phase 2 Terminated
NCT04146051 2025-05-28
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Cartesian Therapeutics
Phase 2 Active not recruiting
NCT05067348 2025-05-01
tMG
Tang-Du Hospital
Phase 2 Recruiting
NCT04728425 2025-04-27
MG_SCIG
University Health Network, Toronto
Phase 2 Completed